Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus
An erratum to this article was published (Diabetes Obes Metab, Feb 2025 ↗)
Authors' conclusion
In a real-world population of US patients with T2DM, tirzepatide was associated with clinically and statistically significant reductions in A1C and body weight. Greater reductions in both A1C and body weight were observed among patients who were GLP1-RA naïve compared to patients switched from GLP1-RA to tirzepatide.
Study context
- Population
- Patients with T2DM from a large urban academic medical centre receiving ≥3 months of continuous tirzepatide1,896 charts reviewed
- Participants
- 612 patients
- Outcome
- Change in HbA1c (A1C) following tirzepatide treatment
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Change in A1C · median 10.4 months
Tirzepatide
1.02
mean · ± 1.48 · %
- Mean A1C reduction 1.02 ± 1.48%
- P < 0.001
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Values |
|---|---|
| Change in body weight | Tirzepatide mean 7.3 ± 9.3 kg |
| Change in BMI | Tirzepatide mean 2.5 kg/m² |
- Change in body weight — Mean reduction in body weight 7.3 ± 9.3 kg
- p < 0.001
- Change in body mass index (BMI) — Mean reduction in BMI
- 2.5 kg/m²
- Change in body weight: 570 patients evaluated for secondary outcomes
A1C lowering and weight loss by prior GLP1-RA treatment
- Greater A1C lowering and weight loss in patients without prior GLP1-RA vs those switched from GLP1-RA
Original publication
Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus. Diabetes Obes Metab. Published 9 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →